Paula Soteropoulos
CIK 1692444 · Chief Executive Officer · last filed 2026-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$966.9K
Companies
4
Total Filings
41
Lifetime Open-Market Net
-$5.79M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DNTH | Director | 0 | $106.62 | $0 | -$2.25M | 7 | 2026-05-22 |
| RLYB | Director | — | $16.69 | — | $0 | 5 | 2025-05-15 |
| QURE | Director | 20,203 | $47.86 | $966.9K | -$1.92M | 22 | 2024-06-17 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Chief Executive Officer | 1,711,079 | — | — | -$1.61M | 5 | 2019-09-30 |
Recent Filings · Page 4 of 5
41 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-09 | QURE | Sell (S) | −11,582 | -$752.3K | EDGAR |
| 2019-09-30 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Mixed | +678,149 | -$8.49M | EDGAR |
| 2019-04-09 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Mixed | — | -$814.8K | EDGAR |
| 2019-03-07 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Mixed | — | -$471.7K | EDGAR |
| 2019-01-30 | QURE | Sell (S) | −1,210 | -$37.9K | EDGAR |
| 2019-01-29 | QURE | Grant (A) | +3,230 | $0 | EDGAR |
| 2019-01-04 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-31 | QURE | Sell (S) | −2,878 | -$53.3K | EDGAR |
| 2018-01-30 | QURE | Grant (A) | +4,792 | $0 | EDGAR |
| 2018-01-04 | AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.